Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer

Tumour cell-extracellular matrix (ECM) interactions are fundamental for discrete steps in breast cancer progression. In particular, cancer cell adhesion to ECM proteins present in the microenvironment is critical for accelerating tumour growth and facilitating metastatic spread. To assess the utility of tumour cell-ECM adhesion as a means for discovering prognostic factors in breast cancer survival, here we perform a systematic phenotypic screen and characterise the adhesion properties of a panel of human HER2 amplified breast cancer cell lines across six ECM proteins commonly deregulated in breast cancer. We determine a gene expression signature that defines a subset of cell lines displaying impaired adhesion to laminin. Cells with impaired laminin adhesion showed an enrichment in genes associated with cell motility and molecular pathways linked to cytokine signalling and inflammation. Evaluation of this gene set in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort of 1,964 patients identifies the F12 and STC2 genes as independent prognostic factors for overall survival in breast cancer. Our study demonstrates the potential of in vitro cell adhesion screens as a novel approach for identifying prognostic factors for disease outcome.

Medienart:

E-Artikel

Erscheinungsjahr:

2016

Erschienen:

2016

Enthalten in:

Zur Gesamtaufnahme - volume:7

Enthalten in:

Oncotarget - 7(2016), 39 vom: 27. Sept., Seite 62939-62953

Sprache:

Englisch

Beteiligte Personen:

Todd, Jason R [VerfasserIn]
Ryall, Karen A [VerfasserIn]
Vyse, Simon [VerfasserIn]
Wong, Jocelyn P [VerfasserIn]
Natrajan, Rachael C [VerfasserIn]
Yuan, Yinyin [VerfasserIn]
Tan, Aik-Choon [VerfasserIn]
Huang, Paul H [VerfasserIn]

Links:

Volltext

Themen:

Breast cancer
Cell adhesion
Cytokines
EC 2.7.10.1
ERBB2 protein, human
Extracellular matrix
HER2
Journal Article
Laminin
Receptor, ErbB-2

Anmerkungen:

Date Completed 18.05.2018

Date Revised 08.04.2022

published: Print

Citation Status MEDLINE

doi:

10.18632/oncotarget.11307

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM263717941